Norbert De Brek

Norbert De Brek

Auto-generated profile, based on publicly available information

Norbert De Brek

Department of Urology, Hôpital européen Georges-Pompidou, AP-HP, Paris, France

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2025 in BJU International
Verified
Journal Article
Closed access
APAdrien Panis
Adrien Panis
TWThibaut Waeckel
Thibaut Waeckel
KBKarim Bensalah
Karim Bensalah
Pierre BigotPierre Bigot
Pierre Bigot
LSLouis Surlemont
Louis Surlemont
AIAlexandre Ingels
Alexandre Ingels

14 August 2026 in The French Journal of Urology
Verified
Journal Article
Closed access
NBNorbert De Brek
Norbert De Brek
APArthur Peyrottes
Arthur Peyrottes
CDCharles Dariane
Charles Dariane
MPMaxime Pattou
Maxime Pattou
ACAlexandra Clerget
Alexandra Clerget
CLCédric Lebacle
Cédric Lebacle

29 May 2026 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Open access
NBNorbert De Brek
Norbert De Brek
APArthur Peyrottes
Arthur Peyrottes
RDRomain Diamand
Romain Diamand
Guillaume PloussardGuillaume Ploussard
Guillaume Ploussard
MOMarco Oderda
Marco Oderda
CDCharles Dariane
Charles Dariane
International Society of Uro-Pathology (ISUP) grade group 2 prostate cancer (GG2 PCa) with suspicion of extraprostatic extension (EPE) on preoperative multiparametric MRI (mpMRI) presents a paradox: an histologically favorable intermediate-risk tumor with aggressive imaging features. We aimed to characterize this population, and identify predictors of pathological upgrading, downstaging, and oncological outcomes after robot-assisted radical prostatectomy (RARP). We analyzed data from 150 patients across 8 European centers with MRI-targeted biopsy-confirmed GG2 PCa and mpMRI-suspected EPE (icT3a), stratified by EPE score, who underwent RARP between 2019 and 2024. Primary endpoint was predictors of pathological upgrading (GG ≥ 3); secondary endpoints included downstaging (pT2), surgical margins, and biochemical recurrence (BCR)-free survival. Patients were divided by EPE score: low (1-2, n = 87) and high (3, n = 38). Pathological upgrading occurred in 36% (55/150), including 10% to GG 4-5. High EPE score was the only significant predictor. Conversely, 46% (69/150) were downstaged to pT2, with low EPE score as main predictor. Positive surgical margins were observed in 30% (45/150). At a median follow-up of 28 months (IQR 17-43), 5-year BCR-free survival was 67% (95% CI 53-85). Posterior/apical EPE on MRI and cT3a stage were linked to higher BCR risk. GG2 PCa with mpMRI-suspected EPE is heterogeneous, showing risks of both upgrading and organ-confined disease. EPE score was the main predictor of both. Despite imaging suspicion, RARP outcomes remained favorable.